Lexeo updates LX2020 cohort data timeline to late Q1/early Q2 2025; LX1001 data at CTAD Oct 2024

Lexeo Therapeutics, Inc.

Expects to share Cohort 1 data from LX2020 for PKP2-ACM in late Q1 or early Q2 2025.
Plans to present LX1001 data for APOE4-associated Alzheimer's at CTAD conference in Oct 2024.
Corporate presentation posted on website; used for investor meetings going forward.
No changes to financial guidance or capital structure disclosed in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.